NASDAQ:PRTG Portage Biotech (PRTG) Stock Price, News & Analysis $2.65 +0.05 (+1.92%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$2.45▼$2.8250-Day Range$0.11▼$5.6052-Week Range$2.10▼$61.99Volume61,044 shsAverage Volume43,432 shsMarket Capitalization$47.17 millionP/E RatioN/ADividend YieldN/APrice Target$170.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Portage Biotech alerts: Email Address Portage Biotech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside6,315.1% Upside$170.00 Price TargetShort InterestHealthy0.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.65) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector438th out of 924 stocksCrude Petroleum & Natural Gas Industry55th out of 81 stocks 3.3 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePortage Biotech has received no research coverage in the past 90 days.Read more about Portage Biotech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.70% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 74.96%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Portage Biotech this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for PRTG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.36% of the stock of Portage Biotech is held by institutions.Read more about Portage Biotech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Portage Biotech are expected to grow in the coming year, from ($0.65) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Portage Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Portage Biotech Stock (NASDAQ:PRTG)Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Read More PRTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTG Stock News HeadlinesAugust 15, 2024 | investorplace.comPRTG Stock Earnings: Portage Biotech Reported Results for Q4 2024August 14, 2024 | finanznachrichten.dePortage Biotech Inc.: Portage Biotech Announces 1-for-20 Reverse Stock SplitAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 13, 2024 | finance.yahoo.comPortage Biotech Announces 1-for-20 Reverse Stock SplitJuly 27, 2024 | finance.yahoo.comPortage Biotech Inc. (PRTG)May 16, 2024 | uk.investing.comPortage Biotech Inc (PRTG)April 14, 2024 | investing.comPortage Biotech halts trial enrollment, seeks strategic optionsApril 12, 2024 | msn.comPortage Down on Announcing AlternativesAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.April 12, 2024 | globenewswire.comPortage Biotech Announces Plans to Expand its Evaluation of Strategic AlternativesMarch 26, 2024 | globenewswire.comPortage Biotech Completes Monetization of Intensity Therapeutics (INTS) sharesMarch 11, 2024 | finance.yahoo.comPRTG: Extending the RunwayMarch 3, 2024 | morningstar.comPortage Biotech Inc PRTGFebruary 28, 2024 | globenewswire.comPortage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business UpdateJanuary 8, 2024 | realmoney.thestreet.comH.C. Wainwright downgrades Portage Biotech on financing overhangJanuary 8, 2024 | realmoney.thestreet.comPortage Biotech just downgraded at H.C. Wainwright, here's whyJanuary 8, 2024 | finance.yahoo.comPRTG: Bridging I-O: Working in Harmony with CheckpointsJanuary 4, 2024 | marketwatch.comPortage Biotech Shares Fall 6% on Job Reductions, Paused Drug Development ProgramSee More Headlines Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2023Today8/22/2024Next Earnings (Estimated)9/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Crude petroleum & natural gas Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$170.00 High Stock Price Target$220.00 Low Stock Price Target$120.00 Potential Upside/Downside+6,315.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-177.66% Return on Assets-129.14% Debt Debt-to-Equity Ratio0.01 Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.45 per share Price / Book0.60Miscellaneous Outstanding Shares17,801,000Free Float10,312,000Market Cap$47.17 million OptionableOptionable Beta1.47 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ian B. Walters M.B.A. (Age 56)M.D., CEO & Chairman of Board Comp: $967.65kMr. Allan J. Lee Shaw CPA (Age 60)Chief Financial Officer Comp: $524.08kDr. Robert A. Kramer Ph.D.Chief Scientific OfficerMr. Brian Wiley (Age 56)Chief Business Officer Comp: $220.69kMr. Justin FairchildVice President of DevelopmentMr. Joseph CiavarellaChief Accounting OfficerMore ExecutivesKey CompetitorsscPharmaceuticalsNASDAQ:SCPHEliem TherapeuticsNASDAQ:ELYMMediWoundNASDAQ:MDWD23andMeNASDAQ:MERezoluteNASDAQ:RZLTView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 164,105 shares on 8/15/2024Ownership: 8.437%View All Institutional Transactions PRTG Stock Analysis - Frequently Asked Questions How have PRTG shares performed this year? Portage Biotech's stock was trading at $36.40 on January 1st, 2024. Since then, PRTG shares have decreased by 92.7% and is now trading at $2.65. View the best growth stocks for 2024 here. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) issued its quarterly earnings data on Wednesday, November, 29th. The company reported ($5.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.40) by $0.40. When did Portage Biotech's stock split? Portage Biotech's stock reverse split on the morning of Thursday, August 15th 2024. The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Portage Biotech's major shareholders? Top institutional investors of Portage Biotech include Armistice Capital LLC (8.44%). How do I buy shares of Portage Biotech? Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTG) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
